Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LTRN |
---|---|---|
09:32 ET | 2782 | 3.17 |
09:33 ET | 2805 | 3.215 |
09:39 ET | 1000 | 3.22 |
09:42 ET | 183 | 3.22 |
09:44 ET | 200 | 3.32 |
09:51 ET | 100 | 3.23 |
10:22 ET | 500 | 3.1809 |
10:27 ET | 202 | 3.2295 |
10:29 ET | 1815 | 3.22 |
10:31 ET | 800 | 3.2501 |
10:56 ET | 400 | 3.21 |
11:00 ET | 100 | 3.3149 |
11:09 ET | 100 | 3.2688 |
11:20 ET | 100 | 3.276 |
11:43 ET | 198 | 3.2287 |
12:03 ET | 100 | 3.29 |
12:12 ET | 949 | 3.3014 |
12:35 ET | 320 | 3.2301 |
12:37 ET | 100 | 3.23 |
12:39 ET | 100 | 3.2547 |
12:46 ET | 317 | 3.255 |
01:11 ET | 200 | 3.26 |
02:20 ET | 700 | 3.305 |
02:21 ET | 780 | 3.2801 |
02:25 ET | 200 | 3.28 |
03:46 ET | 100 | 3.26 |
03:48 ET | 500 | 3.26 |
03:51 ET | 181 | 3.27 |
03:53 ET | 100 | 3.3 |
04:00 ET | 1836 | 3.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Lantern Pharma Inc | 35.6M | -2.0x | --- |
Aeon Biopharma Inc | 34.8M | -0.1x | --- |
NextCure Inc | 37.2M | -0.6x | --- |
Akari Therapeutics PLC | 33.8M | -0.8x | --- |
HST Global Inc | 38.6M | -41.2x | --- |
Passage Bio Inc | 38.9M | -0.4x | --- |
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.56 |
EPS | $-1.65 |
Book Value | $3.82 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.